Additionally, lncRNA BC087858 overexpression is clearly associated with acquired resistance to EGFR-TKI based “gefitinib” therapy [46], while lncRNA GAS5 down-regulation is involved in EGFR-TKI resistance in lung cancer patients and NSCLC cell lines [47]; in both cases, the underlying epigenetic mechanisms have yet to be fully clarified. The gene discussed is EGFR; the disease is lung carcinoma.